UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 82 filers reported holding UROGEN PHARMA LTD in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,566,795 | +51.7% | 111,834 | +12.0% | 0.00% | – |
| Q2 2023 | $1,033,085 | +11.4% | 99,815 | -6.2% | 0.00% | – |
| Q1 2022 | $927,000 | -8.7% | 106,468 | -0.2% | 0.00% | – |
| Q4 2021 | $1,015,000 | -41.5% | 106,716 | +3.4% | 0.00% | – |
| Q3 2021 | $1,735,000 | +17.9% | 103,198 | +7.1% | 0.00% | – |
| Q2 2021 | $1,471,000 | -18.6% | 96,370 | +3.9% | 0.00% | – |
| Q1 2021 | $1,807,000 | +20.5% | 92,723 | +11.4% | 0.00% | – |
| Q4 2020 | $1,500,000 | +3.8% | 83,229 | +11.1% | 0.00% | – |
| Q3 2020 | $1,445,000 | -29.1% | 74,925 | -3.9% | 0.00% | – |
| Q2 2020 | $2,037,000 | +40.5% | 78,005 | -4.0% | 0.00% | – |
| Q1 2020 | $1,450,000 | -46.1% | 81,225 | +0.8% | 0.00% | – |
| Q4 2019 | $2,690,000 | +37.7% | 80,589 | -1.7% | 0.00% | – |
| Q3 2019 | $1,954,000 | -22.6% | 82,008 | +16.7% | 0.00% | – |
| Q2 2019 | $2,526,000 | +808.6% | 70,299 | +834.7% | 0.00% | – |
| Q1 2019 | $278,000 | +33.7% | 7,521 | +80.7% | 0.00% | – |
| Q2 2018 | $208,000 | – | 4,163 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 2,620,545 | $36,713,835 | 6.69% |
| Wildcat Capital Management, LLC | 495,606 | $6,943,440 | 2.79% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 508,883 | $7,129,451 | 2.16% |
| Opaleye Management Inc. | 320,000 | $4,483,200 | 1.46% |
| AlphaCentric Advisors LLC | 165,000 | $2,311,650 | 1.31% |
| Soleus Capital Management, L.P. | 372,000 | $5,211,720 | 0.48% |
| EAM Investors, LLC | 170,523 | $2,389,027 | 0.46% |
| RA Capital Management | 1,483,697 | $20,786,595 | 0.41% |
| Parkman Healthcare Partners LLC | 145,311 | $2,035,807 | 0.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 | $32,265,464 | 0.29% |